Immunome (NASDAQ:IMNM) Stock Keeps “Outperform” Rating at Wedbush

Immunome (NASDAQ:IMNM – Get Free Report)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a report issued on Tuesday, Benzinga reports. They presently have a $35.00 target price on the stock. Wedbush‘s price target indicates a potential upside of 85.87% from the company’s previous close.

Several other research analysts have also weighed in on IMNM. Citigroup reissued a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. William Blair started coverage on Immunome in a research note on Friday, October 16th. They issued an “outperform” rating for the company. Alliance Global Partners started coverage on Immunome in a report on Monday, September 21st. They set a “buy” rating and a $32.00 target price on the stock. Truist Financial lifted their price target on Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen downgraded Immunome from a “sell” rating to a “strong sell” rating in a research report on Sunday, October 4th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $34.25.

Get Our Latest Stock Report on Immunome

Immunome Price Performance

Shares of NASDAQ IMNM traded up $0.06 during mid-day trading on Tuesday, hitting $18.83. 225,617 shares of the company were exchanged, compared to its average volume of 1,359,679. Immunome has a 1-year low of $14.64 and a 1-year high of $30.06. The stock has a 50 day simple moving average of $23.04 and a 200-day simple moving average of $22.50.

Immunome (NASDAQ:IMNM – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). Sell-side analysts forecast that Immunome will post -2.48 EPS for the current year.

Insiders Place Their Bets

In other news, insider Jack Higgins sold 13,200 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $25.32, for a total transaction of $334,224.00. Following the transaction, the insider directly owned 65,050 shares in the company, valued at approximately $1,647,066. This trade represents a 16.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 11,048 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $27.25, for a total transaction of $301,058.00. Following the completion of the transaction, the director directly owned 92,211 shares of the company’s stock, valued at approximately $2,512,749.75. This represents a 10.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 223,368 shares of company stock worth $5,747,142 over the last three months. Company insiders own 7.21% of the company’s stock.

Institutional Trading of Immunome

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMNM. Renaissance Technologies LLC purchased a new stake in shares of Immunome in the 1st quarter valued at approximately $1,507,000. Readystate Asset Management LP boosted its holdings in shares of Immunome by 23.3% in the 2nd quarter. Readystate Asset Management LP now owns 1,605,820 shares of the company’s stock valued at $34,027,000 after buying an additional 303,958 shares in the last quarter. California State Teachers Retirement System boosted its holdings in shares of Immunome by 66.3% in the 1st quarter. California State Teachers Retirement System now owns 111,444 shares of the company’s stock valued at $2,437,000 after buying an additional 44,432 shares in the last quarter. Legal & General Group Plc acquired a new stake in Immunome during the 2nd quarter worth $1,899,000. Finally, Bank of America Corp DE acquired a new stake in Immunome during the 2nd quarter worth $13,729,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

(Get Free Report)

Immunome, Inc (NASDAQ: IMNM) is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based medicines. Its technology platform analyzes human immune responses to identify antibodies that may be developed into therapies for serious diseases.

The company’s research activities have included therapeutic programs in oncology and immunology, with an emphasis on antibodies designed to affect disease-driving biological pathways. Immunome has also conducted antibody discovery work related to infectious diseases, including SARS-CoV-2, as it has expanded its focus toward broader therapeutic applications.

Immunome is headquartered in Exton, Pennsylvania, and serves the global biopharmaceutical market through internal research and development activities and potential collaborations.

Further Reading

Analyst Recommendations for Immunome (NASDAQ:IMNM)

Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.